High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury

Shuo Wang1,3†, Songjie Cai2†, Weitao Zhang1†, Xigao Liu3, Yan Li3, Chao Zhang1, Yigang Zeng1,5, Ming Xu1, Ruiming Rong1,7, Tianshu Yang4, Benkang Shi3, Anil Chandraker2*, Cheng Yang1,6* and Tongyu Zhu1,5*

Abstract

Background: Kidney ischemia reperfusion injury (IRI) is a common cause of acute kidney injury and an unavoidable consequence of kidney transplantation and still lacks specific therapeutics. Recently, mesenchymal stem cell (MSC) has been emerging as a promising cell-based therapy for IRI in the context of transplantation. MSC negatively regulates the secretion of pro-inflammatory as well as the activation of immune cells during IRI through its unique immunosuppressive property.

Methods: We employed mice kidney IRI model and MSC cell line to monitor the IRI related checkpoints. siRNAs were utilized to knock down the potential key factors for mechanistic analysis. Statistical analysis was performed by using one-way ANOVA with Tukey’s post hoc procedure by SPSS.

Results: The expression of high-mobility group box 1 protein (HMGB1) is increased in the acute phase as well as the recovery stage of IRI. Importantly, the HMGB1 upregulation is correlated with the injury severity. HMGB1 diminishes the MSC induced immunosuppressive capacity in the presence of pro-inflammatory cytokines in vitro. Toll like receptor 4 (TLR4)-mediated inducible nitric oxide synthase (iNOS) inhibition contributes to the negative effect of HMGB1 on MSCs. HMGB1-TLR4 signaling inhibition augments the therapeutic efficacy of MSCs in mice renal IRI model.

Conclusions: These findings demonstrate that HMGB1 plays a crucial role in shaping the immunoregulatory property of MSCs within the microenvironments, providing novel insights into the crosstalk between MSCs and microenvironment components, suggesting HMGB1 signals as a promising target to improve MSC-based therapy.

Keywords: Mesenchymal stem cell, HMGB1, Ischemia–reperfusion injury, Acute kidney injury, Cell therapy

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
socioeconomic burden [3, 4]. The treatment essentially relies on supportive modalities and unfortunately no specific therapeutics, are currently available to treat this disorder.

Mesenchymal stem cells (MSCs), or mesenchymal stromal cells, are adult stem cells originating from the mesoderm [5, 6]. For decades, MSCs have been under intensive investigation as a potential treatment for various diseases including kidney injury [7–9]. Unlike embryonic stem cells, MSCs can be feasibly isolated from a variety of tissues and steadily expanded ex vivo, with minimal ethical issues [10]. Importantly, adoptively transferred MSCs have been shown to home to injured tissues and promote tissue repair, indicating that MSCs are able to provide a site-specific treatment [11–13]. In addition, MSCs are devoid of allogeneic rejections due to its immunoprivileged status [14]. Of note, MSCs possess unique immunoregulatory properties that play a key role in the therapeutic function [15]. These characteristics make MSCs an ideal cell-based therapeutic modality for tissue injuries, inflammatory diseases, and allograft rejections.

Despite the documented therapeutic effects in animal models, MSC-based therapeutic regimens are still not widely applied in clinic [16]. The high plasticity of the immunomodulation of MSCs—the immunosuppressive function of MSCs is regulated by the microenvironments—might result in inconsistencies of the treatment outcomes and hamper clinical application [17, 18]. In this respect, a better understanding of the interplay between MSCs and microenvironmental components is essential to improve the reparative property and clinical potential of MSC-based treatment [19].

High-mobility group box 1 (HMGB1) is a nuclear protein that can be released passively and actively during tissue injuries and other pathological processes [20]. As a classic danger associated molecular pattern (DAMP), HMGB1 is able to exacerbate immune responses, which is presumably encountered by MSCs homing to injured tissues [21]. However, it is not clear whether HMGB1 could also regulate the immunosuppressive effects of MSCs. In the present study, we found that HMGB1 dampens the immunosuppressive capacity of MSC in the presence of inflammatory cytokines in vitro and in vivo. Mechanically, Toll like receptor 4 (TLR4)-mediated inducible nitric oxide synthase (iNOS) inhibition might contribute to the effect of HMGB1 on MSCs. These findings demonstrate that HMGB1 plays a crucial role in shaping the immunoregulatory property of MSCs within the microenvironments, providing novel insights into the crosstalk between MSCs and microenvironment components, suggesting HMGB1 signals as a promising target to improve MSC-based therapy.

Methods

Cells and materials
Primary bone marrow-derived MSCs of C57/BL6 mice were purchased from Cyagen Biosciences Inc. (Guangzhou, China). MSCs were cultured in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12) medium with 10% heat-inactivated fetal bovine serum. The present study used MSCs from 6th to 10th passages. Recombinant human HMGB1 was purchased from Sigma-Aldrich (Shanghai, China) and recombinant murine IFN-γ and TNF-α from PeproTech (Southfield, MI, USA). HMGB1 A and B box were synthesized as previously described. HMGB1 and cytokines were dissolved in PBS.

Mouse model of renal ischemia-reperfusion injury
This study was approved by the ethics committee of Zhongshan hospital, Fudan University and performed in accordance with established guidelines for the care and use of laboratory animals. C57/BL6 mice (male, 4–6 weeks of age) obtained from Slac Laboratory (Shanghai, China) were used in all experiments. Mice were housed in a pathogen-free, temperature-controlled environment with a 12 h light/dark cycle and had free access to food and tap water. To induce an established model of renal IRI, mice were anesthetized with 35 mg/kg intraperitoneal sodium pentobarbital. A midline abdominal incision was made and subsequently bilateral renal pedicles were isolated and clamped for 30 min with microvascular clamps. Reperfusion of both kidneys was confirmed after the removal of the clamps. A sham-operated control group was subjected to similar operations without induction of ischemia. All surgical procedures were conducted on a heated pad to keep the body temperature at 37 °C. Two hours after reperfusion, 1 × 10^6 MSCs suspended in 120 μl PBS were adoptively transferred into mice via tail vein. Kidney and blood samples of mice were collected for analysis on day 1 post-injury. The number of mice analyzed per group (5 or 6 mice) was chosen to be sufficient to ensure statistical analysis.

Kidney function
Serum creatinine (Scr) and blood urea nitrogen (BUN) were examined as indicators of renal function by using QuantiChrom Creatinine Assay Kit and QuantiChrom Urea Assay Kit (BioAssay Systems, Hayward, CA, USA) separately.

Renal histology
Kidney histology was evaluated with formalin-fixed, hematoxylin and eosin (H&E)-stained sections in a blinded manner as described previously. Five different regions of the corticomedullary junction from each mouse was randomly selected and measured. The
histological alterations were indicated as ATN score, which was quantified on a 0 to 5 scale according to the percentage of tubular necrosis, tubular dilation and cast formation (0, none; 1, <11%; 2, 11% to 25%; 3, 26% to 45%; 4, 46% to 75%; 5, >75%).

TdT mediated dUTP nick end labeling (TUNEL) assay
To determine the apoptotic magnitude of kidney tissues in response to IRI and MSCs treatment, kidney sections were subjected to TUNEL staining by using In Situ Cell Death Detection Kit (Roche, Indianapolis, USA) according to the manufacturer’s protocol. The number of TUNEL-positive cells was counted under light microscope at ×200 magnification in a blinded manner. Five areas at the corticomedullary junction from each mouse of different groups were assessed.

Detection of serum cytokines
The concentrations of serum TNF-α, IL-1β, IL-6 and HMGB1 were detected with ELISA kits purchased from R&D Systems (Boston, MA, USA) according to the manufacturer’s instructions.

T cell proliferation and activation assay
CD4⁺ T cells were purified from spleens of C57BL/6 mice by CD4⁺ T Cell Isolation Kit (Miltenyi Biotec). Freshly isolated T cells were labeled with 2.5 μM CFSE (Invitrogen) and co-cultured with MSCs at different ratios in a Transwell system in the presence of anti-CD3/CD28 microbeads (Invitrogen). After 3 days, T cells were collected and CFSE levels were determined by flow cytometry. For T cell activation detection, CD4⁺ T cells were collected and then incubated with anti-mouse CD4-PE/Cy7 and IFN-γ-PE (Biolegend, SanDiego, CA, USA) for 1 h in dark. The percentage of IFN-γ-positive cells was measured by flow cytometry.

Lymphocyte infiltration in kidneys
For detection of the lymphocyte infiltration in kidneys, kidney tissues were decapsulated, diced, and digested in collagenase type IV (1 mg/ml, Stemcell Technologies, Vancouver, British Columbia, Canada) for 30 min at 37 °C and then passed through 40 μm Falcon meshes followed by red cell lysis. Renal single cells were washed 3 times with PBS and incubated with anti-mouse CD3-APC, CD4-PE/Cy7 and CD8-PE (Biolegend, SanDiego, CA, USA) for 1 h at 4 °C and detected on FACSCaliber Analyzer (BD Biosciences, San Jose, CA, USA). Data was processed using FlowJo software (Ashland, OR, USA).

Real-time quantitative polymerase chain reaction (qPCR)
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer’s protocol. First-strand cDNA was synthesized using Reverse Transcription Kit (Takara, Dalian, China). Real-time PCR was performed using SYBR Green PCR mix (Roche, Indianapolis, USA) on an ABI Prism® 7500HT Sequence Detection System (Applied Biosystems, CA, USA). The mRNA expression levels of genes of interest were presented as fold exchange that was normalized to β-actin expression in control group. Primer sequences used in the present study are listed in Additional file 2: Table S1.

Western blotting
Cultured cells were collected and lysed in RIPA buffer containing protease and phosphatase inhibitors on ice to obtain total proteins. Cell protein extracts were electrophoresed on SDS–polyacrylamide gels and then transferred onto nitrocellulose membranes, followed by blocking in 5% nonfat milk for 1 h at room temperature. The membranes were incubated with primary antibodies at indicated dilutions overnight at 4 °C. After incubation with secondary antibodies for 1 h at room temperature, the immunoblot bands were visualized by chemiluminescence and analyzed using ImageJ software.

Knockdown of RAGE and TLR4 by small interfering RNA (siRNA)
Receptor for advanced glycation end products (RAGE) and TLR4 siRNA were designed and produced by GenePharma (Shanghai, China). RAGE siRNA sequence: sense: GCCAGAAAUUGUGGAUCCUTT; antisense: AGGAUC CACAAUUUCUGGCTT. TLR4 siRNA sequence: sense: GCUUAAGCUUCUCCAAUUUTT; antisense: AAAUUG GAGAAGCUAUGGCTT. Negative control (NC): sense: UUCCGAGAAGGUCACGUTT; antisense: ACGUGA CACGUUCCGAGAATT. The siRNA was transfected into MSCs using Lipofectamine 3000 (Invitrogen) according the manufacturer’s instructions. Briefly, MSCs were subjected to the mixture of siRNA and Lipofectamine 3000 reagent in serum-free DMEM medium for 6 h. And then medium was changed and the cells were harvested for the further experiments.

Statistical analysis
Data are presented as mean±standard deviation of replicates. Statistical analysis was performed by using one-way ANOVA with Tukey’s post hoc procedure by SPSS 19.0 software (SPSS Inc., Armonk, NY, USA). A value of P<0.05 was considered statistically significant.

Results
HMGB1 expression is upregulated in serum and kidney during renal ischemia–reperfusion injury
Renal ischemia–reperfusion injury (IRI) is a common reason in prerenal injury. Although it has been reported
that HMGB1 is increased during renal IRI, the dynamics of HMGB1 expression after reperfusion is still not fully understood [22–24]. To determine the possible effect of HMGB1 on MSCs within kidneys, we first examine the renal expression of HMGB1 during IRI in the conditions of different ischemia time and different reperfusion time. Postulating that local HMGB1 release might be concomitant with kidney injury, we also measured Scr and BUN levels simultaneously as markers of renal function. As shown in Fig. 1a, b, both HMGB1 mRNA and protein levels increased significantly at day 1 post-IRI with ischemia times of 30 min and 45 min. Figure 1b–d exhibited a similar alteration of Scr and BUN with HMGB1, indicating a positive correlation between HMGB1 release and kidney dysfunction at the early stage of IRI. Furthermore, we subjected mice to bilateral renal pedicles clamping for 30 min and observed the dynamic changes of HMGB1 and kidney function following reperfusion. HMGB1 mRNA and protein were obviously upregulated at day 1 (Fig. 1e, f). Western blot analysis demonstrated that HMGB1 protein continued to increase up to day 5 and remained elevated at day 7. However, in contrast to HMGB1, both Scr and BUN peaked at day 1 and recovered thereafter (Fig. 1g). Importantly, these data suggested that the upregulation of HMGB1 lasts through the early and recovery phase of IRI which is the main therapeutic window of MSC-based treatment for renal IRI (Fig. 1e–h). Moreover, we detected the serum concentration of HMGB1 and found that renal IRI could also result in a significant increase of HMGB1 in serum (Fig. 1i).

HMGB1 suppresses the immunosuppressive capacity of MSCs in the presence of pro-inflammatory cytokines

As a DAMP, HMGB1 is able to promote inflammation through interaction with a large spectrum of immune cells. However, it is still unclear whether HMGB1 could modulate the immunoregulatory property of MSCs. As we known, T cell proliferation and interferon-γ (IFN-γ) expression experiments are well-documented and widely applied tools to assess the immune response in vivo. We therefore tested the immune regulatory effect of HMGB1-pretreated MSCs with these experiments. CD4+ T cells stimulated with anti-CD3 and anti-CD28-coated microbeads were co-cultured with HMGB1-pretreated MSCs in a Transwell system. As expected, a suppression of T cell proliferation by untreated MSCs was observed in CFSE assay (Fig. 2a). Importantly, preconditioning with HMGB1 alone barely showed effect on the immunosuppressive capacity of MSCs. It is prevailingly believed that the combination of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) is essential to prime naïve MSCs immunoregulatory. Therefore, we further detected the inhibition of T cell proliferation by MSCs pretreated with IFN-γ and TNF-α in the presence or absence of HMGB1. Due to the well-documented pro-inflammatory function of HMGB1, we hypothesized that HMGB1 could augment the immunosuppression of MSCs in a concerted action with pro-inflammatory cytokines. We found that pro-inflammatory cytokines significantly enhanced the immunosuppressive capacity of MSCs on T cell proliferation. Concurrent conditioning with pro-inflammatory cytokines and HMGB1, surprisingly, partially reversed the immune regulatory effect of MSCs compared with pro-inflammatory cytokines-pretreated MSCs. Similarly, addition of HMGB1 could also obviously diminished pro-inflammatory cytokines-induced immunosuppression of MSCs on T cell activation based on intracytoplasmic IFN-γ detection using flow cytometry (Fig. 2b). To verify these observations, we determined T cell proliferation...
and activation at graded MSC/T cell ratios of 1:20, 1:40 and 1:80. As shown in Fig. 2a, b, a dose-dependent immunosuppression of MSCs was demonstrated and the reversal effect of HMGB1 was confirmed at different ratios. These data demonstrated that HMGB1 impairs the immunosuppressive capacity of MSCs in the presence of pro-inflammatory cytokines.

**HMGB1 diminishes the therapeutic effects of MSCs in mice kidney IRI model**

To fully interpret the impact of HMGB1 on MSCs, we further delineated the therapeutic effect of HMGB1-pre-treated MSCs in a murine model of renal IRI. We subjected mice to a regular 30 min bilateral renal IRI and administered MSCs 2 h after reperfusion through the tail vein. MSCs were pre-incubated with and without pro-inflammatory cytokines in the presence or absence of HMGB1 for 24 h. As shown in Fig. 3, IRI caused significant functional damage to the kidneys as expected. Histological analysis showed tubular necrosis, tubular dilatation and cast formation accompanied by increased ATN scores in mice subjected to renal IRI. Compared with vehicle-treated sham control group, IRI also resulted in significant apoptosis within kidneys, exhibited as a dramatic increase in TUNEL-positive cells. In line with previous studies, administration of MSCs significantly reduced the levels of Scr and BUN, improved histological damage and diminished apoptosis [27, 28]. MSCs pre-primed with pro-inflammatory cytokines demonstrated an improvement in therapeutic effect. However, pre-treating MSCs along with HMGB1 could only partially reverse the augmented treatment of MSCs induced by pro-inflammatory cytokines. These data indicate that HMGB1 diminishes the therapeutic effects of MSCs in the presence of inflammation.

**HMGB1 reduces the anti-inflammation effect of MSCs in vivo**

To verify the regulatory effect of HMGB1 on immunosuppression of MSCs in vivo, the inflammatory status during kidney injuries was measured. We first examined the inflammatory cytokine levels in serum and kidney using ELISA and qPCR assay separately. As shown in Fig. 4a, b, the serum concentrations and kidney mRNA levels of TNF-α, IL-1β and IL-6 were dramatically increased due to IRI and treatment with MSCs could indeed alleviate the inflammation. We found, as expected, that pretreatment with pro-inflammatory cytokines enhanced the immunoregulatory ability of MSCs. Importantly, this pro-inflammatory cytokine-induced augmentation of inflammation suppression was obviously reversed by concurrent conditioning with HMGB1. To further evaluate the kidney inflammation, we next detected the lymphocyte infiltration into kidneys using flow cytometry. Similar results were obtained that MSCs treated with a combination of HMGB1 and pro-inflammatory cytokines demonstrated a significant reduction in the inhibition of the extensive lymphocyte infiltration during IRI, compared with MSCs primed by pro-inflammatory cytokines (Fig. 4c). These results were consistent with the histological findings and indicated that conditioning with HMGB1 in the presence of pro-inflammatory cytokines render MSCs less immunosuppressive.

**HMGB1 reverses the pro-inflammatory cytokine-induced iNOS mRNA expression through TLR4**

As iNOS plays an indispensable role in mediating the immunosuppressive property of murine MSCs [29], we further determined whether HMGB1 could modulate the expression of iNOS in MSCs in a series of dose–response and time course studies. Under the conditions of different concentrations of IFN-γ and TNF-α (Fig. 5a) as well as different time points (Fig. 5b), HMGB1 could still reduce the iNOS expression in MSCs. As shown in Fig. 5c, iNOS mRNA was indeed inhibited by HMGB1 in a dose-dependent manner in the presence of IFN-γ and TNF-α. Similar results were obtained for B box that serves as the main functional subunit of HMGB1. It has been reported that MSCs, on stimulation with inflamed environments, also produce chemokines which play a synergetic role with immunosuppressive molecules in the immunomodulation of MSCs [29]. In this regard, we detected the mRNA expression of CCL2, CCL5, CXCL9 and CXCL10 in MSCs treated by inflammatory cytokines and HMGB1. Data revealed that HMGB1 had minor effects on these chemokines (Fig. 5d).

Given that HMGB1 has been reported to signal mainly through TLR2, TLR4 and RAGE, the expression of these receptors in MSCs was examined by western blot analysis [30]. Cell expression of all three receptors was confirmed.
in the Raw 264.7 cell line which acted as a positive control, instead, only RAGE and TLR4 were expressed on MSCs (Fig. 5e). To further determine the role of RAGE and TLR4 on the effect of HMGB1, siRNAs targeting RAGE and TLR4 were used. The knockdown efficacy was demonstrated by western blot (Additional file 1: Fig. S1). Compared with negative control (NC) siRNA and RAGE siRNA, TLR4 siRNA could partially abolish the inhibition of HMGB1 on the iNOS mRNA expression of MSCs (Fig. 5f).

**HMGB1-TLR4 signaling inhibition is a promising strategy for improving MSC-based therapeutic modality**

Within injured kidneys, elevated HMGB1 is proposed to promote inflammatory responses, which indirectly prime MSCs with immunosuppressive properties; on the other hand, it also directly weakens the immunomodulatory efficacy of MSCs through the engagement of TLR4. To circumvent this issue, we adopted a HMGB1-blocking strategy to reinforce the immunosuppression-based therapeutic effect. Before administration in animal models, we repeated T cell proliferation and activation assay in TLR4 siRNA-treated MSCs in the presence of IFN-γ, TNF-α and HMGB1 and we found that TLR4 siRNA enhanced the immunoregulatory function of MSCs (Fig. 6a, b). In a subsequent IRI study, we pre-conditioned MSCs with HMGB1 A box (a specific antagonist) or TLR4 siRNA to prevent the impact of HMGB1 in the microenvironment within kidneys. As shown in Fig. 6c–e, both strategies improved the reparative efficacy of MSCs.

**Discussion**

Recent studies have shown the immunoregulatory effect of MSC in immune disorders, for instance, graft-versus-host disease (GvHD), cardiovascular diseases, liver diseases and autoimmune diseases [31]. In the context of solid organ transplantation, it has been well accepted that the immunosuppressive character of MSC plays a critical role in the reparative effects in IRI [18, 31]. However, the immunosuppression is not an inherent property of MSCs, but adaptively 'empowered' by the inflamed microenvironment. Specifically, inflammatory cytokines are required to elicit the immunomodulatory effects of MSCs, among which IFN-γ in the concomitant presence of at least one other cytokines, including TNF-α, IL-1α and IL-1β, is essential [32].

While a permissive microenvironment is essential, the magnitude of the immunosuppressive properties of MSCs is dynamically orchestrated by the surrounding molecular network. It is reported that the pro-inflammatory cytokine IL-17 can enhance the immunosuppressive effect of MSCs by increasing the stability of iNOS mRNA [33]. Conversely, the anti-inflammatory cytokine TGF-β renders MSCs less immunosuppressive through inhibiting iNOS or IDO expression via Smad3 pathways [34]. Likewise, the concurrent addition of IL-10 further diminishes the immunosuppression of MSCs. Unexpectedly, several immunosuppressive drugs including cyclosporine, tacrolimus and dexamethasone that are widely used for organ transplantation and autoimmune disease in clinic routines, can still impair the immunoregulation of MSCs [35–38]. Collectively, it seems like the immunomodulatory factors could paradoxically favor the immune responses towards the opposite side via shaping the bioactivity of MSCs [29, 31]. Despite great progress have been made in this field, the interplay between the MSCs and the components in the microenvironment is not fully delineated.

DAMPs, in the microenvironment, play a critical role in regulating immune responses, angiogenesis and tissue remodeling [21, 39]. HMGB1 is identified as one of the most important members [20]. Previous studies reported the upregulation of HMGB1 in kidney IRI, kidney transplantation and other kidney injuries [40–42]. In this study, we further found that HMGB1 upregulation is correlated with the injury severity. And we also verified the expression of HMGB1 is increased not only in the acute phase of IRI, but also during the recovery stage. HMGB1 can promote inflammation through pattern recognition receptors expressed on a wide spectrum of both innate and adaptive immune cells. For instance, HMGB1 is able to stimulate dendritic cell maturation and migration, and to mediate the proliferation and cytokine production of T cells [43–46]. According to the theory mentioned above, HMGB1 is proposed to act in synergy with pro-inflammatory cytokines to augment the immunosuppression of MSCs. Ironically, as a key initiator of inflammatory responses, HMGB1 indeed antagonisms the immunosuppressive capacity of MSC ‘licensed’ by the inflamed environments, indicating more complexities in
Fig. 4  HMGB1 impaired the anti-inflammation efficacy of MSCs in vivo.  

a Renal mRNA levels of TNF-α, IL-1β and IL-6 were analyzed by qPCR.  
b Serum levels of TNF-α, IL-1β and IL-6 were determined by ELISA.  
c Intact kidneys were decapsulated, diced, and digested for single cell suspensions.  
Renal single cells were then incubated with anti-mouse CD3, CD4 and CD8 antibodies and subsequently analyzed by flow cytometry. Data were shown as mean ± SD (n = 6 mice per group). *P < 0.05
Fig. 5  HMGB1 inhibited iNOS mRNA expression via TLR4. a MSCs were treated with HMGB1, A box or B box at indicated concentrations for 24 h in the presence or absence of IFN-γ and TNF-α (5 ng/ml). mRNA level of iNOS was analyzed by qPCR. b MSCs were treated with IFN-γ and TNF-α at graded concentrations for 24 h in the presence or absence of HMGB1 (1 μg/ml). mRNA level of iNOS was analyzed by qPCR. c MSCs were treated with IFN-γ and TNF-α (5 ng/ml) in the presence or absence of HMGB1 (1 μg/ml). mRNA level of iNOS was analyzed by qPCR at indicated time point. d MSCs were treated with HMGB1 at indicated concentrations for 24 h in the presence or absence of IFN-γ and TNF-α (5 ng/ml). mRNA level of chemokines was analyzed by qPCR. e Receptors were determined by western blot. MSCs were treated with HMGB1 in the presence or absence of IFN-γ and TNF-α. RAGE or TLR4 siRNA were administrated, and iNOS mRNA f was examined. Each data point represented the average value of triplicated wells from each independent experiment. Data were pooled from three independent experiments. Data were shown as mean ± SD. *P < 0.05, **P < 0.01
that TLR4 triggering render MSCs a pro-inflammatory phenotype and therefore proposed a dichotomy of MSC1 and MSC2 according to the concept of M1 and M2 macrophages [54]. Adding more uncertainty, some researchers showed no obvious effect of TLR activation on the immunoregulatory function of MSCs [55, 56]. Discrepancies in experimental set-ups may explain, at least in part, the contradictory findings in this field and therefore more investigation is warranted in the future to clarify the contribution of TLR4 to the immune-related activities of MSCs.

To date, most studies regarding the effects of HMGB1 on MSCs have focused on the migration and differentiation capacities. Early research found that HMGB1 potentiates migration [57–60]. On the contrary, recent studies demonstrated apoptotic cells are responsible for the recruitment of MSCs via hepatocyte growth factor (HGF) while HMGB1 released from necrotic cells can reversely inhibit the migration by reducing HGF receptor of MSCs [61, 62]. In terms of differentiation capacities, HMGB1 is reported to facilitate MSC differentiation towards osteoblasts [57, 60, 63, 64], endothelial cells and smooth muscle cells [65]. In addition, HMGB1 can still inhibit the proliferation and regulate the secretion of MSCs [58, 60, 64]. In this scenario, the possible impact of HMGB1 blocking on the biology of MSCs should take into account in subsequent studies.

It is of interest to compare kidney progenitor/stem cells with MSCs. Previous studies have implicated the existence of CD133+CD24− renal progenitor/stem cells within adult human kidneys that could differentiate toward the podocyte as well as the tubular lineage [66, 67]. Despite similarities between these cell types in therapeutic potential for renal injury, differences exist in cell-surface markers. Well-accepted markers for MSCs include CD73+CD90+CD105+CD45−CD34−CD14−CD79−HLA-DR− [29]. However, due to the paucity of specific markers to study in situ MSCs, our knowledge of the physiological function of endogenous MSCs is limited. Recently, lineage tracing studies have identified GLI1+ kidney resident MSCs, that is helpful for further in situ investigations [68].
In this study, we carried out experiments in murine MSCs. It is notable that human MSCs use indoleamine 2, 3-dioxygenase (IDO) but not iNOS as the key immunosuppressive factor [29]. Consistently with our findings, Ramin Lotfi et al. have demonstrated that HMGB1 could decrease IDO expression in human MSCs [69]. Nevertheless, whether HMGB1 has similar effect on human MSCs remains elusive. To address this issue, a separate but more extensive experiment will be designed.

**Conclusions**

MSC-based therapy serves as an emerging and promising modality to provide site-specific immunoregulation to treat tissue injuries and inflammation-related disorders. An adequate understanding of the interplay between MSC and the microenvironment is of vital importance to optimize MSC’s therapeutic potential. In this study, we found that HMGB1 could diminish the immunosuppressive capacity of MSC in the presence of pro-inflammatory cytokines in vitro and in vivo. Importantly, we further demonstrated that HMGB1 signaling inhibition strategies would augment the therapeutic effect of MSC on renal IRI. Our research may provide a novel ‘checkpoint’ to improve MSC-based therapies.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12967-020-02334-8.

Additional file 1: Figure S1. The knockdown efficacy of TLR4 siRNA and RAGE siRNA.

Additional file 2: Table S1. Primers used in qRT-PCR.

**Abbreviations**

AKI: Acute kidney injury; MSCs: Mesenchymal stem cells; HMGB1: High-mobility group box 1 protein; DAMP: Danger associated molecular pattern; TLR4: Toll like receptor 4; IRI: Ischemia–reperfusion injury; IFN-γ: Interferon-γ; TNF-α: Tumor necrosis factor-α; HGF: Hepatocyte growth factor; iNOS: Inducible nitric oxide synthase; qPCR: Real-time quantitative polymerase chain reaction; TUNEL: TdT mediated dUTP nick end labeling assay; Scr: Serum creatinine; BUN: Blood urea nitrogen; siRNA: Small interfering RNA; RAGE: Receptor for advanced glycation end products; MyD88: Myeloid differentiation primary-response protein; TRIF: Toll/interleukin (IL)-1 receptor domain-containing adaptor-protein inducing interferon-β; IRF3: Interferon regulatory factor 3.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

AC, TZ and CY conceived, designed the study, collected the data and performed data analysis and interpretation. TY designed the study and synthesized HMGB1 A and B box. SW, SC and WZ performed the research, collected the data, and wrote the manuscript. XL, YL, CZ and YZ performed the research. RR, MX and BS revised the manuscript. All authors read and approved the final manuscript.
Funding
This study was supported by National Key R&D Program of China (2018YFA0107501 to Ruiming Rong, 2018YFA0107502 to Cheng Yang), National Natural Science Foundation of China (81770746 to Cheng Yang, 81900685 to Shuo Wang, 81770747 to Ruiming Rong and 81873621 to Tongyu Zhu), Medical and Health Talents T—aining Plan for the Excellent Youth of Shanghai Municipal (2018YQ50 to Cheng Yang) and Shanghai Rising-Star Program (19QD1406300 to Cheng Yang).

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its additional files.

Ethics approval and consent to participate
Human subjects: Not applicable. Animals: This study was approved by the ethics committee of Zhongshan hospital, Fudan University and performed in accordance with established guidelines for the care and use of laboratory animals.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Urology, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory of Organ Transplantation, 180 Fenglin Road, Shanghai 200032, China. 2 Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Ave, LMRC 301, Boston, MA 02115, USA. 3 Department of Urology, Qilu Hospital of Shandong University, Jinan 250012, China. 4 Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China. 5 Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China. 6 Fudan Zhangjiang Institute, Shanghai 212033, China. 7 Department of Transfusion, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Received: 10 January 2020 Accepted: 8 April 2020
Published online: 20 April 2020

References

1. Kellum JA, Bellomo R, Ronco C. Progress in prevention and treatment of acute kidney injury: moving beyond kidney attack. JAMA. 2018;320:437–8.

2. Mehta RL, Cerda J, Burdmann EA, Tonelli M, Garcia-Garcia G, Jha V, Beguin Y, Krzesinski JM, Jouret F. Mesenchymal stromal cell therapy in organ transplantation. Front Cell Dev Biol. 2014;2:8.

3. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD,Susantitaphong P, Rocco M, Vanholder R, Sever MS, et al. International society of nephrology’s Oby25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385:2616–43.

4. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet. 2013;382:170–9.

5. Yang L, Xing G, Wang L, Wu Y, Li S, Xu G, He Q, Chen J, Chen M, Liu X, et al. Acute kidney injury in China: a cross-sectional survey. Lancet. 2015;386:1465–71.

6. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008;2:313–9.

7. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36.

8. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34:747–54.

9. Guo K, Ikahara S, Meng X. Mesenchymal stem cells for inducing tolerance in organ transplantation. Front Cell Dev Biol. 2014;2:8.

10. Erpicum P, Detrey O, Weeks L, Bonvoisin C, Lechanteur C, Briquet A, Beguin Y, Krzesinski JM, Joreet F. Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrol Dial Transplant. 2014;29:1487–93.

11. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21:216–25.

12. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:206–16.

13. Detante O, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, Barbier E, Desreut MD, De Frapiot P, Segebarth C, et al. Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplant. 2009;18:1369–79.

14. Herrera MB, Bussolati B, Bruno S, Morando L, Mauriello-Romanzozi G, Sanavio F, Stamenkovic I, Biancone L, Camussi G. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007;72:430–41.

15. Le Blanc K, Mougakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12:383–96.

16. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012;33:136–43.

17. Peirel AJ, Sisti A, Romagnani P. Mesenchymal stem cell-based therapy for kidney disease: a review of clinical evidence. Stem Cells Int. 2016;2016:4798639.

18. Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, Wang CY. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19:35–42.

19. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392–402.

20. Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, Shi Y. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med. 2012;1:51–8.

21. Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, et al. HMGBl in health and disease. Mol Aspects Med. 2014;40:1–116.

22. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGBl): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.

23. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, Chadban SJ. HMGBl contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol. 2010;21:1878–90.

24. Chung KY, Park JJ, Kim YS. The role of high-mobility group box 1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc. 2008;40:2136–8.

25. Wu H, Chen G, Wyburn KR, Yin J, Bertollo P, Erris JM, Alexander SJ, Sharland AF, Chadban SJ. TL4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117:2847–59.

26. Huang Y, Yin H, Han J, Huang J, Xu J, Zheng F, Tan Z, Fang M, Rui L, Chen D, et al. Extracellular hmgbl functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant. 2007;7:799–808.

27. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Heusar H, Susarla SM, Ullola L, Wang H, DiRaimo R, et al. Reversing established sepsis with antagonists of endogenous high–mobility group box 1. Proc Natl Acad Sci USA. 2004;101:296–301.

28. Wise AF, Williams TM, Kiewiet MB, Payne NL, Siatskas C, Samuel CS, Ricardo SD. Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2014;306:F1222–35.

29. Smedo P, Palasio CG, Oliveiro CD, Feitosa CG, Goncalves GM, Cenedese MA, Wang PM, Teixeira VP, Rei MA, Fachecho-Silva A, Camara NO. Early modulation of inflammation by mesenchymal stem cell after acute kidney injury. Int Immunopharmacol. 2009;9:677–82.

30. Shi Y, Wang L, Qi L, Liu K, Hou J, Shao C, Wang Y. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14:493–507.

31. Ibrahim ZA, Armour CL, Phipps S, Sukkar MB. RAGE and TLRs: relatives, friends or neighbours? Mol Immunol. 2013;56:739–44.

32. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15:1009–16.

33. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141–50.

34. Han X, Yang Q, Lin L, Xu C, Zheng C, Chen X, Han Y, Li M, Cao W, Cao K, et al. Interleukin-17 enhances immunosuppression by mesenchymal stem cells. Cell Death Differ. 2014;21:1758–68.
34. Xu C, Yu P, Han X, Du L, Gan J, Wang Y, Shi Y. TGF-beta promotes immune responses in the presence of mesenchymal stem cells. J Immunol. 2014;192:103–9.

35. Chen X, Gao Y, Li W, Su J, Zhang Y, Huang Y, Roberts Al, Han Y, Li J, Wang Y, Shi Y. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis. 2014;5:e1009.

36. Eggenhofer E, Renner P, Sieder Y, Popp FC, Hoogduijn MJ, Geissler EK, Schlitt HJ, Dahlke MH. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol. 2011;25:141–7.

37. Buron F, Perrin H, Alacuc C, Hequet O, Thaunat O, Khlopp-Sarda MN, Moulin FT, Moelon E. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplant Proc. 2009;41:3477–52.

38. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation. 2006;81:1589–95.

39. Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol. 2015;6:422.

40. Chen Q, Guan X, Zuo X, Wang J, Yin W. The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharmacol Sin. 2016;6:183–8.

41. Zhou TB. Role of high mobility group box 1 and its signaling pathways in renal diseases. J Recept Signal Transduct Res. 2014;34:348–50.

42. Zhu P, Xie L, Ding HS, Gong Q, Yang J, Yang L. High mobility group box 1 and kidney diseases (review). Int J Mol Med. 2013;31:763–8.

43. Sundberg E, Fasth AE, Palmblad K, Andersson U. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology. 2009;214:303–9.

44. Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P. Toll-like receptor triggering in cord blood mesenchymal stem cells. Transpl Immunol. 2011;25:141–7.

45. Raicevic G, Najar M, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, Tourougouz M, Lagneau L. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol. 2011;270:207–16.

46. van den Berk LC, Jansen BJJ, Siebers-Veermolen KG, Netea MG, Latuhibin H, Bergevoet S, Raymakers RA, Kooger G, Fogter CC, Adema GJ, Toensma R. Toll-like receptor triggering in cord blood mesenchymal stem cells. J Cell Mol Med. 2009;13:3415–26.

47. Lin F, Zhang W, Xue D, Zhu T, Li J, Chen E, Yao X, Pan Z. Signalling pathways involved in the effects of HMGB1 on mesenchymal stem cell migration and osteoblastic differentiation. Int J Mol Med. 2016;37:789–97.

48. Lin F, Xue D, Xie T, Pan Z. HMGB1 promotes cellular chemokine synthesis and potentiates mesenchymal stromal cell migration via Rap1 activation. Mol Med Rep. 2016;14:1283–9.

49. Xie HL, Zhang Y, Huang YZ, Li S, Wu CG, Jiao XF, Tan MY, Huang YC, Deng L. Regulation of high mobility group box 1 and hypoxia in the migration of mesenchymal stem cells. Cell Biol Int. 2014;38:892–7.

50. Feng L, Xue D, Chen W, Hang H, Jin J, Wang J, Wang H, Wu C, Wang L. High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cells Dev. 2008;17:805–13.

51. Vogel S, Borger V, Peters C, Forster M, Liebfried P, Metzger K, Meisel R, Daubener W, Trapp T, Fischer JC, et al. Necrotic cell-high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apototic cell death. Cell Death Differ. 2015;22:1219–30.

52. Vogel S, Chattejee M, Metzger K, Borst O, Geiser T, Seizer P, Muller L, Mack A, Schumann S, Bruihn JH, et al. Activated platelets interfere with recruitment of mesenchymal stem cells to apoptotic cardiac cells via high mobility group box 1/Toll-like receptor 4-mediated down-regulation of hepatocyte growth factor receptor MET. J Biol Chem. 2014;289:11068–82.

53. Xue D, Zhang W, Chen E, Gao X, Liu L, Ye C, Tan Y, Pan Z, Li H. Local delivery of HMGB1 in gelatin sponge scaffolds combined with high mobility group box 1 stell cells accelerates to fracture healing. Oncotarget. 2017;8;42098–115.

54. Feng L, Xue D, Chen W, Zhang W, Gao O, Xu J, Feng Y, Pan Z. HMGB1 promotes the secretion of multiple cytokines and potentiates the osteogenic differentiation of mesenchymal stem cells through the Ras/MAPK signaling pathway. Exp Ther Med. 2016;12:3941–7.

55. Meng X, Chen M, Su W, Tao X, Sun M, Zou X, Ying R, Wei W, Wang B. The differentiation of mesenchymal stem cells to vascular cells regulated by the HMGB1/RAE1 axis: its application in cell therapy for transplant arteriosclerosis. Stem Cell Res Ther. 2018;9:85.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.